

# Lars H Lund

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7856514/publications.pdf>

Version: 2024-02-01

384  
papers

36,624  
citations

7551

77  
h-index

3997

176  
g-index

391  
all docs

391  
docs citations

391  
times ranked

26621  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of heart failure: a comprehensive and updated review of epidemiology. <i>Cardiovascular Research</i> , 2023, 118, 3272-3287.	1.8	517
2	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	1.8	23
3	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. <i>Europace</i> , 2022, 24, 48-57.	0.7	10
4	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2022, 19, 100-116.	6.1	156
5	Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 761-769.	1.8	11
6	Implementation science and potential for screening in heart failure. <i>European Heart Journal</i> , 2022, 43, 413-415.	1.0	7
7	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the <sc>DIAMOND</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	2.9	32
8	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-CHF trial. <i>ESC Heart Failure</i> , 2022, 9, 164-177.	1.4	5
9	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 756-767.	1.4	9
10	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the <sc>ESC-HFA EORP</sc> Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
11	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 132-142.	2.9	30
12	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
13	Left atrial reservoir strain improves diagnostic accuracy of the 2016 ASE/EACVI diastolic algorithm in patients with preserved left ventricular ejection fraction: insights from the KARUM haemodynamic database. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1157-1168.	0.5	29
14	Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 715-726.	1.2	6
15	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	1.0	12
16	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure. <i>ESC Heart Failure</i> , 2022, 9, 822-833.	1.4	23
17	Cardiac remodelling—Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
18	Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the <sc>Swedish Heart Failure Registry</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 871-884.	2.9	33

#	ARTICLE	IF	CITATIONS
19	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118.	1.4	4
20	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. European Journal of Heart Failure, 2022, 24, 1047-1062.	2.9	37
21	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	1.0	14
22	Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study. ESC Heart Failure, 2022, 9, 2125-2138.	1.4	3
23	Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2063-2069.	1.4	22
24	Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1171-1179.	2.9	16
25	An update on global epidemiology in heart failure. European Heart Journal, 2022, 43, 3005-3007.	1.0	26
26	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	2.9	22
27	Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	2.9	10
28	Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality. European Journal of Heart Failure, 2022, 24, 1212-1222.	2.9	10
29	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062.	0.7	19
30	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish AHF Registry. JACC: Heart Failure, 2022, 10, 380-392.	1.9	5
31	Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database. Circulation: Heart Failure, 2022, 15, .	1.6	30
32	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	1.0	5
33	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170.	2.9	13
34	Left ventricular ejection fraction as the primary heart failure phenotyping parameter. European Journal of Heart Failure, 2022, 24, 1158-1161.	2.9	15
35	Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2022, 24, 1636-1646.	2.9	9
36	Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes. Journal of the American Heart Association, 2022, 11, .	1.6	2

#	ARTICLE	IF	CITATIONS
37	Acknowledging the complex puzzle that links heart failure hospitalizations to outcomes. Letter regarding the article "Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort". European Journal of Heart Failure, 2021, 23, 683-683.	2.9	1
38	Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?: Reply. European Journal of Heart Failure, 2021, 23, 342-343.	2.9	0
39	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. Heart, 2021, 107, 229-236.	1.2	26
40	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. American Journal of Medicine, 2021, 134, 482-489.	0.6	53
41	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
42	Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. European Journal of Heart Failure, 2021, 23, 476-485.	2.9	46
43	Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. Journal of Internal Medicine, 2021, 289, 895-905.	2.7	35
44	Diagnostic utility of right atrial reservoir strain to identify elevated right atrial pressure in heart failure. International Journal of Cardiology, 2021, 324, 227-232.	0.8	10
45	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	2.9	181
46	The Differential Impact of the Left Atrial Pressure Components on Pulmonary Arterial Compliance-Resistance Relationship in Heart Failure. Journal of Cardiac Failure, 2021, 27, 277-285.	0.7	5
47	Do we need a definition of acute heart failure with preserved ejection fraction?. Annals of Medicine, 2021, 53, 1473-1478.	1.5	0
48	Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations. Frontiers in Cell and Developmental Biology, 2021, 9, 640723.	1.8	11
49	A case report about successful treatment of refractory ventricular tachycardia with ablation under prolonged haemodynamic support with extracorporeal membrane oxygenation. European Heart Journal - Case Reports, 2021, 5, ytab084.	0.3	1
50	Electrostatic Discharge Causing Pump Shutdown in HeartMate 3. JACC: Case Reports, 2021, 3, 459-463.	0.3	5
51	Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. ESC Heart Failure, 2021, 8, 1827-1839.	1.4	15
52	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022.	2.9	33
53	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	1.6	13
54	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. Scientific Reports, 2021, 11, 4885.	1.6	31

#	ARTICLE	IF	CITATIONS
55	The <sc>Heart Failure Association Atlas</sc>: <sc>Heart Failure Epidemiology and Management Statistics</sc> 2019. European Journal of Heart Failure, 2021, 23, 906-914.	2.9	130
56	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
57	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <sc>Heart Failure Association of the European Society of Cardiology</sc>. European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
58	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	0.7	18
59	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle "œdo no harm"? European Journal of Heart Failure, 2021, , .	2.9	0
60	Association Between $\hat{I}^2$ -Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. Journal of Cardiac Failure, 2021, 27, 1165-1174.	0.7	17
61	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 973-982.	2.9	65
62	Use of loop diuretics in chronic heart failure: do we adhere to the <sc>Hippocratic</sc> principle "œdo no harm"? European Journal of Heart Failure, 2021, 23, 1068-1075.	2.9	4
63	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation, 2021, 143, 2129-2142.	1.6	101
64	Accuracy of echocardiographic estimates of pulmonary artery pressures in pulmonary hypertension: insights from the KARUM hemodynamic database. International Journal of Cardiovascular Imaging, 2021, 37, 2637-2645.	0.7	9
65	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. European Journal of Heart Failure, 2021, 23, 1698-1707.	2.9	37
66	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. European Journal of Internal Medicine, 2021, 89, 65-75.	1.0	18
67	Cardiac, renal, and metabolic effects of sodium-glucose cotransporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	2.9	36
68	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. Journal of Cardiac Failure, 2021, 27, 756-765.	0.7	20
69	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the <sc>KaRen</sc> study. ESC Heart Failure, 2021, 8, 4243-4254.	1.4	13
70	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 2021, 42, 3741-3752.	1.0	74
71	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	2.0	32
72	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	0.7	14

#	ARTICLE	IF	CITATIONS
73	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
74	New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e89-e90.	1.4	2
75	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. ESC Heart Failure, 2021, 8, 4955-4967.	1.4	26
76	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. International Journal of Cardiology, 2021, 343, 63-72.	0.8	23
77	Accuracy and diagnostic performance of doppler echocardiography to estimate mean pulmonary artery pressure in heart failure. Echocardiography, 2021, 38, 1624-1631.	0.3	1
78	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1844-1854.	2.9	42
79	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	2.9	32
80	Methodological issues in meta-analyses of real-world clinical data to infer causality. International Journal of Cardiology, 2021, 345, 107-108.	0.8	0
81	Time is prognosis™ in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Failure, 2021, 8, 4444-4453.	1.4	37
82	297 Echocardiographic biventricular coupling index to predict pre-capillary pulmonary hypertension. European Heart Journal Supplements, 2021, 23, .	0.0	0
83	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. Journal of Cardiac Failure, 2020, 26, 673-684.	0.7	5
84	Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. International Journal of Cardiology, 2020, 298, 59-65.	0.8	44
85	Recurrent hyperkalemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review. CKJ: Clinical Kidney Journal, 2020, 13, 714-719.	1.4	18
86	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 86-93.	1.4	27
87	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 313-323.	0.4	10
88	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. Circulation, 2020, 141, 4-6.	1.6	81
89	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	2.9	81
90	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. American Heart Journal, 2020, 222, 93-104.	1.2	4

#	ARTICLE	IF	CITATIONS
91	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
92	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	2.9	131
93	Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation. <i>European Journal of Heart Failure</i> , 2020, 22, 113-125.	2.9	23
94	Iron deficiency in heart failure. <i>International Journal of Cardiology</i> , 2020, 299, 207.	0.8	0
95	<sc>Heart Failure Association</sc> of the <sc>European Society of Cardiology</sc> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	2.9	66
96	Association Between $\beta$ -Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e007180.	1.6	12
97	If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation. <i>European Journal of Heart Failure</i> , 2020, 22, 1888-1890.	2.9	1
98	Atrial fibrillation in heart failure with preserved ejection fraction: a risk marker, risk factor or confounder?. <i>Heart</i> , 2020, 106, 1949-1949.	1.2	2
99	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 2029-2044.	1.6	117
100	Critical appraisal of the instantaneous end-diastolic pulmonary arterial wedge pressures. <i>ESC Heart Failure</i> , 2020, 7, 4247-4255.	1.4	3
101	Pragmatic approaches to the next generation of clinical trials in heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 282-283.	1.4	3
102	Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm <sc>CREAtinine</sc> Measurements (<sc>SCREAM</sc>) project. <i>European Journal of Heart Failure</i> , 2020, 22, 1790-1799.	2.9	21
103	Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction: Treating Resistance, Impedance, and Compliance. <i>Journal of Cardiac Failure</i> , 2020, 26, 662-663.	0.7	0
104	SO057BETA-BLOCKERS ARE ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND ADVANCED CHRONIC KIDNEY DISEASE: COHORT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
105	Heart Failure in Patients Undergoing Elective and Emergency Noncardiac Surgery: Still a Poorly Addressed Risk Factor. <i>Journal of Cardiac Failure</i> , 2020, 26, 1034-1042.	0.7	7
106	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	2.9	101
107	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 1016-1021.	0.7	29
108	Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. <i>ESC Heart Failure</i> , 2020, 7, 3633-3643.	1.4	19

#	ARTICLE	IF	CITATIONS
109	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. ESC Heart Failure, 2020, 7, 3438-3451.	1.4	13
110	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. Circulation Research, 2020, 127, 1261-1273.	2.0	38
111	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International Journal of Cardiology, 2020, 313, 76-82.	0.8	30
112	Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. ESC Heart Failure, 2020, 7, 1534-1546.	1.4	28
113	Optimizing diastolic pressure gradient assessment. Clinical Research in Cardiology, 2020, 109, 1411-1422.	1.5	3
114	Epidemiology, pathophysiology and contemporary management of cardiogenic shock – A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	2.9	244
115	A registry-based algorithm to predict ejection fraction in patients with heart failure. ESC Heart Failure, 2020, 7, 2388-2397.	1.4	13
116	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. European Journal of Heart Failure, 2020, 22, 1649-1658.	2.9	49
117	Abnormalities of Potassium in Heart Failure. Journal of the American College of Cardiology, 2020, 75, 2836-2850.	1.2	94
118	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. ESC Heart Failure, 2020, 7, 2098-2112.	1.4	23
119	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Failure, 2020, 7, 727-736.	1.4	7
120	Validation of non-invasive ramp testing for HeartMate 3. ESC Heart Failure, 2020, 7, 663-672.	1.4	11
121	Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEDish evaluation of left Ventricular Assist Device (SweVAD) trial. European Journal of Heart Failure, 2020, 22, 739-750.	2.9	17
122	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2020, 22, 1390-1398.	2.9	33
123	Circulating neuregulin-1 in heart failure with preserved and reduced left ventricular ejection fraction. ESC Heart Failure, 2020, 7, 445-455.	1.4	11
124	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432.	3.0	59
125	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	2.9	83
126	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36



#	ARTICLE	IF	CITATIONS
127	Induction immunosuppression strategies and long-term outcomes after heart transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13871.	0.8	15
128	Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1551-1567.	2.9	93
129	Induction Therapy after Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, S277.	0.3	0
130	Congestion and Diuretic Resistance in Acute or Worsening Heart Failure. <i>Cardiac Failure Review</i> , 2020, 6, e25.	1.2	16
131	Association between use of beta-blockers and mortality/morbidity in patients with heart failure with reduced, midrange or preserved ejection fraction and advanced chronic kidney disease. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
132	Treatment with sacubitril/valsartan in European outpatients with chronic heart failure in Europe: results from ARIADNE registry. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
133	Comparison of various instantaneous pulmonary arterial wedge pressure measurements with prognostic validation. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
134	An epigenetic circuit linking oxidative stress and DNA hydroxymethylation in heart failure. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
135	Baseline characteristics and clinical features of patients with heart failure with reduced ejection fraction: a European real-world, non-interventional registry study. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
136	Safety of sacubitril/valsartan in heart failure outpatients with chronic heart failure in real life in Europe: results from ARIADNE registry. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
137	Death, hospitalization, emergency department visits and out-patient visits in patients with heart failure in contemporary practice: results from the prospective European 9069-patient ARIADNE registry. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
138	Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm Creatinine Measurements (SCREAM) project. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1534-1541.	0.4	40
139	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
140	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. <i>Uppsala Journal of Medical Sciences</i> , 2019, 124, 65-69.	0.4	68
141	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
142	Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. <i>International Journal of Cardiology</i> , 2019, 274, 202-207.	0.8	10
143	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. <i>Europace</i> , 2019, 21, 1776-1784.	0.7	22
144	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27

#	ARTICLE	IF	CITATIONS
145	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019, 140, 1359-1361.	1.6	16
146	Continuous flow mechanical circulatory support is not associated with early graft failure: An analysis of the International Society for Heart and Lung Transplantation registry. <i>Clinical Transplantation</i> , 2019, 33, e13752.	0.8	3
147	Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the Swedish heart failure register. <i>Scandinavian Journal of Primary Health Care</i> , 2019, 37, 434-443.	0.6	8
148	Feasibility and accuracy of tricuspid annular displacement assessed by speckle tracking echocardiography and Doppler tissue imaging. <i>Echocardiography</i> , 2019, 36, 2004-2009.	0.3	4
149	Incidence of, Associations With and Prognostic Impact of Worsening Renal Function in Heart Failure With Different Ejection Fraction Categories. <i>American Journal of Cardiology</i> , 2019, 124, 1575-1583.	0.7	20
150	Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 471-479.	2.9	41
151	Increasing Complexity of Heart Failure Therapy Requires Earlier and More Frequent Referral. <i>Journal of Cardiac Failure</i> , 2019, 25, 317-318.	0.7	4
152	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 830-839.	1.4	18
153	Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1465-1472.	0.7	7
154	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	2.9	223
155	The additive value of echocardiographic pulmonary to left atrial global strain ratio in the diagnosis of pulmonary hypertension. <i>International Journal of Cardiology</i> , 2019, 292, 205-210.	0.8	8
156	Reply. <i>JACC: Heart Failure</i> , 2019, 7, 533-534.	1.9	0
157	Sacubitril/valsartan eligibility and outcomes in the ESC/EORP/HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
158	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC/EORP/HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170
159	Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2019, 8, e011737.	1.6	39
160	2019 EACTS Expert Consensus on long-term mechanical circulatory support. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 230-270.	0.6	255
161	The GUIDE heart failure risk prediction model: another fish in the sea?. <i>European Journal of Heart Failure</i> , 2019, 21, 779-780.	2.9	0
162	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224

#	ARTICLE	IF	CITATIONS
163	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. JACC: Heart Failure, 2019, 7, 306-317.	1.9	125
164	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 139, 1458-1460.	1.6	49
165	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. Clinical Research in Cardiology, 2019, 108, 1394-1405.	1.5	30
166	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. International Journal of Cardiology, 2019, 287, 66-72.	0.8	14
167	Early and Late Right Heart Failure Following LVAD Implantation: Epidemiology, Natural History and Outcomes. An Analysis of the STS INTERMACS Database. Journal of Heart and Lung Transplantation, 2019, 38, S20.	0.3	2
168	Diagnosis of Heart Failure. Cardiovascular Medicine, 2019, , 83-101.	0.0	2
169	Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. Scandinavian Cardiovascular Journal, 2019, 53, 14-20.	0.4	5
170	ST2 in heart failure with preserved and reduced ejection fraction. Scandinavian Cardiovascular Journal, 2019, 53, 21-27.	0.4	40
171	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT / Overlock 1	2.9	65
172	PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction. Journal of Cardiac Failure, 2019, 25, 1012-1013.	0.7	0
173	Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. Clinical Research in Cardiology, 2019, 108, 703-715.	1.5	51
174	Time-dependent prognostic effects of recipient and donor age in adult heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 174-183.	0.3	19
175	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC: Heart Failure, 2019, 7, 65-76.	1.9	62
176	Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 3-13.	2.9	84
177	VA-ECMO Support in Nonsurgical Patients With Refractory Cardiogenic Shock: Pre-Implant Outcome Predictors. Artificial Organs, 2019, 43, 132-141.	1.0	19
178	Improving long-term outcomes with left ventricular assist devices: referral, selection, experience, and technology. European Journal of Heart Failure, 2019, 21, 101-102.	2.9	8
179	Clinical and research implications of serum versus plasma potassium measurements. European Journal of Heart Failure, 2019, 21, 536-537.	2.9	18
180	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	1.0	123

#	ARTICLE	IF	CITATIONS
181	Heart failure and the risk of acute kidney injury in relation to ejection fraction in patients undergoing coronary artery bypass grafting. <i>International Journal of Cardiology</i> , 2019, 274, 66-70.	0.8	11
182	Focusing on Referral Rather than Selection for Advanced Heart Failure Therapies. <i>Cardiac Failure Review</i> , 2019, 5, 24-26.	1.2	25
183	Improving outcomes in heart failure requires improving implementation of heart failure therapy. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 869-870.	0.3	0
184	Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. <i>ESC Heart Failure</i> , 2018, 5, 302-308.	1.4	12
185	Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use. <i>European Journal of Heart Failure</i> , 2018, 20, 931-932.	2.9	14
186	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1326-1334.	2.9	156
187	Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1217-1226.	2.9	116
188	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	153
189	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 254, 203-209.	0.8	14
190	Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. <i>Heart</i> , 2018, 104, 1093-1100.	1.2	25
191	Is ejection fraction in heart failure a limitation or an opportunity?. <i>European Journal of Heart Failure</i> , 2018, 20, 431-432.	2.9	17
192	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 246-256.	1.9	47
193	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
194	Temporal Trends of De Novo Malignancy Development After Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 40-49.	1.2	70
195	Running Out of Success in HF Therapy ?. <i>Journal of Cardiac Failure</i> , 2018, 24, 63-64.	0.7	0
196	Complex relationships between comorbidity, outcomes, and treatment effect in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 511-513.	2.9	6
197	Negotiating renal dysfunction when treating patients with heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 113-122.	0.6	7
198	The year in cardiology 2017: heart failure. <i>European Heart Journal</i> , 2018, 39, 832-839.	1.0	5

#	ARTICLE	IF	CITATIONS
199	Heart failure: a weak link in CHA <sub>2</sub> DS <sub>2</sub> -VASc. ESC Heart Failure, 2018, 5, 231-239.	1.4	8
200	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. Journal of Cardiac Failure, 2018, 24, 365-374.	0.7	32
201	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2018, 121, 1558-1566.	0.7	19
202	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239
203	Optimizing outcomes after heart transplantation. European Journal of Heart Failure, 2018, 20, 395-397.	2.9	11
204	Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEEâ€HF) study. European Journal of Heart Failure, 2018, 20, 152-160.	2.9	29
205	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	2.9	69
206	Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. European Journal of Heart Failure, 2018, 20, 769-777.	2.9	18
207	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 3-15.	2.9	157
208	Complexities of the Global Heart Failure Epidemic. Journal of Cardiac Failure, 2018, 24, 813-814.	0.7	8
209	Heart transplantation outcomes for rheumatic heart disease: Analysis of international registry data. Clinical Transplantation, 2018, 32, e13439.	0.8	2
210	Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. European Heart Journal, 2018, 39, 4257-4265.	1.0	38
211	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14%964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. European Heart Journal, 2018, 39, 4277-4284.	1.0	189
212	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	2.9	555
213	Impaired left atrial dynamics and its improvement by guided physical activity reveal left atrial strain as a novel early indicator of reversible cardiac dysfunction in rheumatoid arthritis. European Journal of Preventive Cardiology, 2018, 25, 1106-1108.	0.8	23
214	Cardiomyopathy, oxidative stress and impaired contractility in a rheumatoid arthritis mouse model. Heart, 2018, 104, 2026-2034.	1.2	28
215	Venoarterial extracorporeal membrane oxygenation for postcardiotomy shock: Risk factors for mortality. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1894-1902.e3.	0.4	61
216	Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis. Journal of Heart and Lung Transplantation, 2018, 37, 1207-1217.	0.3	32

#	ARTICLE	IF	CITATIONS
217	Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. <i>International Journal of Cardiology</i> , 2018, 267, 128-132.	0.8	28
218	Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1013-1020.	0.3	37
219	Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 415-422.	1.0	7
220	Controller and battery changes due to technical problems related to the HVAD® left ventricular assist device - a single center experience. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 74.	0.4	5
221	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
222	Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	4
223	A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 267-273.	1.8	26
224	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. <i>European Heart Journal</i> , 2018, 39, 3439-3450.	1.0	375
225	Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges. <i>European Journal of Heart Failure</i> , 2018, 20, 370-372.	2.9	1
226	Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. <i>Cardiac Failure Review</i> , 2018, 4, 70.	1.2	9
227	The continued value of risk scores in advanced heart failure. <i>Kardiologia Polska</i> , 2018, 76, 1299-1300.	0.3	1
228	Effectiveness of cardiovascular implantable electronic devices with a defibrillator component therapy according to ventricular assist device implant strategy: data from the PCHF-VAD registry. <i>Cardiologia Croatica</i> , 2018, 13, 358-360.	0.0	0
229	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 366-376.	2.9	28
230	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	107
231	Effects of Spinal Cord Stimulation on Cardiac Sympathetic Nerve Activity in Patients with Heart Failure. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 504-513.	0.5	10
232	Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study. <i>European Journal of Heart Failure</i> , 2017, 19, 1107-1116.	2.9	94
233	Spinal cord stimulation in heart failure: effect on disease-associated biomarkers. <i>European Journal of Heart Failure</i> , 2017, 19, 283-286.	2.9	5
234	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. <i>Current Heart Failure Reports</i> , 2017, 14, 59-70.	1.3	72

#	ARTICLE	IF	CITATIONS
235	Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1275-1285.	1.2	102
236	Association between demographic, organizational, clinical, and socioeconomic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1270-1279.	2.9	86
237	Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 629-635.	0.5	40
238	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017, 103, 1156-1162.	1.2	10
239	HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. <i>International Journal of Cardiology</i> , 2017, 228, 709-716.	0.8	38
240	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	177
241	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2606-2618.	1.2	79
242	Optimal Eligibility Criteria for Trials in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 528-529.	0.7	3
243	Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure. <i>Open Heart</i> , 2017, 4, e000568.	0.9	25
244	Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, midrange, and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1606-1614.	2.9	148
245	Digoxin: beneficial or harmful?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 127-128.	1.4	3
246	The Inescapable Heterogeneity of Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 351-352.	0.7	10
247	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>CLINICAL PERSPECTIVE. Circulation: Heart Failure</i> , 2017, 10, e003534.	1.6	14
248	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 14-24.	1.9	57
249	The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. <i>Heart and Vessels</i> , 2017, 32, 735-749.	0.5	6
250	Incretin-based therapy for type 2 diabetes: A real class effect?. <i>International Journal of Cardiology</i> , 2017, 227, 141-142.	0.8	2
251	A comprehensive population-based characterization of heart failure with midrange ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1624-1634.	2.9	196
252	Pre-Implant Outcome Predictors in Patients With Refractory Cardiogenic Shock Supported With VA-ECMO. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2094-2096.	1.2	5

#	ARTICLE	IF	CITATIONS
253	Ivabradine in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	23
254	Hyperkalemia After Initiating Renin-“Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	123
255	Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 565-574.	1.9	236
256	Rituximab Induction and Risk of Cardiac Allograft Vasculopathy, Rejection and Death. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, S88.	0.3	3
257	The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report“2017; Focus Theme: Allograft ischemic time. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1047-1059.	0.3	624
258	Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Lung and Heart-Lung Transplantation Report“2017; Focus Theme: Allograft ischemic time. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1070-1079.	0.3	61
259	The Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Heart Transplantation Report“2017; Focus Theme: Allograft ischemic time. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1060-1069.	0.3	109
260	The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report“2017; Focus Theme: Allograft ischemic time. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1037-1046.	0.3	645
261	Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	18
262	Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue. <i>International Journal of Cardiology</i> , 2017, 249, 77-78.	0.8	1
263	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1081-1088.	1.1	21
264	An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1137-1153.	0.3	142
265	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017, 226, 65-70.	0.8	4
266	Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease. <i>European Journal of Heart Failure</i> , 2017, 19, 88-97.	2.9	43
267	Trends in the use of mechanical circulatory support as a bridge to heart transplantation across different age groups. <i>International Journal of Cardiology</i> , 2017, 231, 225-227.	0.8	21
268	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.3	49
269	Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management“An analysis of the International Society for Heart and Lung Transplantation Registry. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 407-417.	0.3	67
270	Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart Transplantation. <i>Heart Lung and Circulation</i> , 2017, 26, 143-149.	0.2	9



#	ARTICLE	IF	CITATIONS
271	HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGF-1R. Journal of Cardiac Failure, 2017, 23, 293-303.	0.7	25
272	Global Public Health Burden of Heart Failure. Cardiac Failure Review, 2017, 03, 7.	1.2	1,731
273	249Long-term outcome in myocardial infarction patients with heart failure treated with aldosterone receptor antagonist in relation to ejection fraction and kidney function. European Heart Journal, 2017, 38, .	1.0	0
274	P2300Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines. European Heart Journal, 2017, 38, .	1.0	0
275	Anaemia and iron deficiency in heart failure: epidemiological gaps, diagnostic challenges and therapeutic barriers in sub-Saharan Africa. Cardiovascular Journal of Africa, 2017, 28, 331-337.	0.2	0
276	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. International Journal of Cardiology, 2016, 220, 595-601.	0.8	59
277	Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. European Journal of Heart Failure, 2016, 18, 503-511.	2.9	121
278	Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart, 2016, 3, e000324.	0.9	66
279	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. Heart, 2016, 102, 1464-1471.	1.2	15
280	Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction in Sweden. Value in Health, 2016, 19, A650-A651.	0.1	1
281	First Annual IMACS Report: A global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. Journal of Heart and Lung Transplantation, 2016, 35, 407-412.	0.3	98
282	Risk scores and biomarkers in heart failure: A journey to predictive accuracy and clinical utility. Journal of Heart and Lung Transplantation, 2016, 35, 711-713.	0.3	9
283	Cardiac resynchronization therapy: results, challenges and perspectives for the future. Scandinavian Cardiovascular Journal, 2016, 50, 282-292.	0.4	6
284	The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-Lung Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. Journal of Heart and Lung Transplantation, 2016, 35, 1196-1205.	0.3	63
285	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. JACC: Heart Failure, 2016, 4, 870-880.	1.9	58
286	Unmet Needs and Prioritization in Heart Failure. Journal of Cardiac Failure, 2016, 22, 587-588.	0.7	5
287	Heart, lung, and vascular registries: Evolving goals, successful approaches, and ongoing innovation. Journal of Heart and Lung Transplantation, 2016, 35, 1149-1157.	0.3	26
288	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). International Journal of Cardiology, 2016, 220, 750-758.	0.8	13

#	ARTICLE	IF	CITATIONS
289	Heart Failure With "Mid-Range" Ejection Fraction" New Opportunities. <i>Journal of Cardiac Failure</i> , 2016, 22, 769-771.	0.7	25
290	The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report"2016; Focus Theme: Primary Diagnostic Indications for Transplant. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1158-1169.	0.3	522
291	The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report"2016; Focus Theme: Primary Diagnostic Indications for Transplant. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1185-1195.	0.3	138
292	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	33
293	Effect of Heart Rate and Use of Beta Blockers on Mortality After Heart Transplantation. <i>American Journal of Cardiology</i> , 2016, 118, 1916-1921.	0.7	20
294	Arterial-ventricular and interventricular interaction in isolated post-capillary and combined pulmonary hypertension in severe mitral stenosis. <i>European Journal of Applied Physiology</i> , 2016, 116, 1545-1554.	1.2	1
295	Survival After Coronary Artery Bypass Grafting in Patients With Preoperative Heart Failure and Preserved vs Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 530.	3.0	42
296	ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives. <i>Evidence-Based Medicine</i> , 2016, 21, 33-34.	0.6	0
297	Increases in Cardiac Output and Oxygen Consumption During Enhanced External Counterpulsation. <i>Heart Lung and Circulation</i> , 2016, 25, 1133-1136.	0.2	14
298	Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 218-228.	1.4	18
299	Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. <i>Heart</i> , 2016, 102, 257-259.	1.2	59
300	A comprehensive assessment of the association between anemia, clinical covariates and outcomes in a population-wide heart failure registry. <i>International Journal of Cardiology</i> , 2016, 211, 124-131.	0.8	13
301	The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1-23.	0.3	1,096
302	Cardiovascular Diseases in ¼30,000 Patients in the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 949-958.	1.2	35
303	The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Heart Transplantation Report"2015; Focus Theme: Early Graft Failure. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1233-1243.	0.3	130
304	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. <i>European Journal of Heart Failure</i> , 2015, 17, 680-688.	2.9	77
305	Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality. <i>Clinical Interventions in Aging</i> , 2015, 10, 1547.	1.3	16
306	Association between renin"angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2015, 36, 2318-2326.	1.0	83

#	ARTICLE	IF	CITATIONS
307	Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. <i>European Journal of Heart Failure</i> , 2015, 17, 612-619.	2.9	55
308	The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Reportâ€™2015; Focus Theme: Early Graft Failure. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1255-1263.	0.3	71
309	Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1283-1291.	0.3	55
310	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	0.8	7
311	Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. <i>Heart</i> , 2015, 101, 592-599.	1.2	23
312	Association Between Use of Statins and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 252-260.	1.6	37
313	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of â‰¥50%. <i>Circulation: Heart Failure</i> , 2015, 8, 862-870.	1.6	83
314	Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 17, jev144.	0.5	47
315	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. <i>International Journal of Cardiology</i> , 2015, 189, 6-11.	0.8	17
316	The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Reportâ€™2015; Focus Theme: Early Graft Failure. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1244-1254.	0.3	464
317	The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Reportâ€™2015; Focus Theme: Early Graft Failure. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1264-1277.	0.3	465
318	Prognostic Significance of Resting Heart Rate and Use of Î²-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 871-879.	1.6	119
319	Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. <i>Open Heart</i> , 2015, 2, e000260.	0.9	16
320	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. <i>Europace</i> , 2015, 17, 424-431.	0.7	55
321	Abstract 12273: Benefits and Safety of Prolonged Dual Antiplatelet Therapy in Patients With Ischemic Cardiovascular Disease: A Meta-analysis of 18 Randomized Trials Including 94,306 Patients. <i>Circulation</i> , 2015, 132, .	1.6	0
322	Abstract 12849: Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, .	1.6	0
323	Acylation of ghrelin is increased in heart failure and decreases post heart transplantation. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 343-348.	0.4	5
324	Awareness of indications for device therapy among a broad range of physicians: a survey study. <i>Europace</i> , 2014, 16, 1580-1586.	0.7	17

#	ARTICLE	IF	CITATIONS
325	Age, prognostic impact of <sc>QRS</sc> prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14â€‰%713 patients in the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2014, 16, 1073-1081.	2.9	54
326	Predicting survival in heart failure: validation of the <sc>MAGGIC</sc> heart failure risk score in 51 043 patients from the <sc>S</sc>wedish <sc>H</sc>eart <sc>F</sc>ailure <sc>R</sc>egistry. <i>European Journal of Heart Failure</i> , 2014, 16, 173-179.	2.9	134
327	Emergency Parallel Mechanical Circulatory Support for Ventricular Fibrillation. <i>Circulation: Heart Failure</i> , 2014, 7, 229-230.	1.6	2
328	Assessment of a University of California, Los Angeles 4â€‰Variable Risk Score for Advanced Heart Failure. <i>Journal of the American Heart Association</i> , 2014, 3, e000998.	1.6	13
329	HeartWare left ventricular assist device thrombosis in aspirin non-responder. <i>Asian Cardiovascular and Thoracic Annals</i> , 2014, 22, 203-204.	0.2	6
330	Association Between Use of Î²-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2008.	3.8	142
331	Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. <i>Heart</i> , 2014, 100, 1235-1241.	1.2	93
332	Triage of Patients With Moderate to Severe Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 661-671.	1.2	40
333	Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. <i>International Journal of Cardiology</i> , 2014, 175, 55-61.	0.8	13
334	Biomarkers in advanced heart failureâ€”pathophysiology leading to clinical use?. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1213-1214.	0.3	6
335	The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Pediatric Lung and Heartâ€”Lung Transplantation Reportâ€”2014; Focus Theme: Retransplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1025-1033.	0.3	84
336	The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Pediatric Heart Transplantation Reportâ€”2014; Focus Theme: Retransplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 985-995.	0.3	120
337	Association between cardiovascular vs. nonâ€”cardiovascular coâ€”morbidity and outcomes in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 992-1001.	2.9	119
338	The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heartâ€”Lung Transplant Reportâ€”2014; Focus Theme: Retransplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1009-1024.	0.3	451
339	Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. <i>International Journal of Cardiology</i> , 2014, 174, 360-367.	0.8	56
340	The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Reportâ€”2014; Focus Theme: Retransplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 996-1008.	0.3	490
341	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 112-121.	0.7	40
342	Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for heart transplantation. <i>American Heart Journal</i> , 2014, 168, 325-331.	1.2	18

#	ARTICLE	IF	CITATIONS
343	The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Reportâ€”2013; Focus Theme: Age. Journal of Heart and Lung Transplantation, 2013, 32, 965-978.	0.3	479
344	The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Lung and Heart-Lung Transplantation Reportâ€”2013; Focus Theme: Age. Journal of Heart and Lung Transplantation, 2013, 32, 989-997.	0.3	97
345	Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator: A pilot study. Journal of Heart and Lung Transplantation, 2013, 32, 651-654.	0.3	6
346	Modifications of skeletal muscle ryanodine receptor type 1 and exercise intolerance in heart failure. Journal of Heart and Lung Transplantation, 2013, 32, 925-929.	0.3	32
347	The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Reportâ€”2013; Focus Theme: Age. Journal of Heart and Lung Transplantation, 2013, 32, 979-988.	0.3	201
348	The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Reportâ€”2013; Focus Theme: Age. Journal of Heart and Lung Transplantation, 2013, 32, 951-964.	0.3	561
349	Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. European Heart Journal, 2013, 34, 529-539.	1.0	132
350	Peripheral Extracorporeal Membrane Oxygenation as Short-Term Right Ventricular Support After HeartWare Left Ventricular Assist Device Implantation. ASAIO Journal, 2013, 59, 523-525.	0.9	6
351	Association of Spironolactone Use With All-Cause Mortality in Heart Failure. Circulation: Heart Failure, 2013, 6, 174-183.	1.6	38
352	Aldosterone Inhibition in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 310, 205.	3.8	3
353	Left Ventricular Assist Devices: From Bridge to Transplant to Destination Therapy. , 2013, , 385-423.		0
354	Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2012, 308, 2108.	3.8	153
355	Derived and Displayed Power Consumption, Flow, and Pulsatility Over a Range of HeartMate II Left Ventricular Assist Device Settings. ASAIO Journal, 2012, 58, 183-190.	0.9	18
356	Management of Left Ventricular Rupture After Myocardial Infarction Solely With ECMO. Circulation: Heart Failure, 2012, 5, e65-7.	1.6	10
357	Heart failure with a preserved ejection fraction additive value of an exercise stress echocardiography. European Heart Journal Cardiovascular Imaging, 2012, 13, 656-665.	0.5	44
358	Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace, 2012, 14, 1148-1155.	0.7	69
359	The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy. Journal of Heart and Lung Transplantation, 2011, 30, 315-325.	0.3	72
360	Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM). Journal of Heart and Lung Transplantation, 2011, 30, 1236-1243.	0.3	71

#	ARTICLE	IF	CITATIONS
361	Myocardial recovery in peri-partum cardiomyopathy after continuous flow left ventricular assist device. <i>Journal of Cardiothoracic Surgery</i> , 2011, 6, 150.	0.4	17
362	Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 175.	3.8	59
363	Leptin resistance after heart transplantation. <i>European Journal of Heart Failure</i> , 2010, 12, 516-520.	2.9	13
364	Extracorporeal membrane oxygenation as a rescue of intractable ventricular fibrillation and bridge to heart transplantation. <i>European Journal of Heart Failure</i> , 2010, 12, 301-304.	2.9	18
365	Comparison Across Races of Peak Oxygen Consumption and Heart Failure Survival Score for Selection for Cardiac Transplantation. <i>American Journal of Cardiology</i> , 2010, 105, 1439-1444.	0.7	26
366	What are the true prognostic differences between heart failure with preserved and reduced ejection fraction?. <i>European Journal of Heart Failure</i> , 2010, 12, 98-98.	2.9	1
367	Individual rights and autonomy in clinical research. <i>European Journal of Heart Failure</i> , 2010, 12, 311-312.	2.9	3
368	Patient selection for left ventricular assist devices. <i>European Journal of Heart Failure</i> , 2010, 12, 434-443.	2.9	145
369	Change in blood pressure during hospitalisation for acute heart failure predicts mortality. <i>Scandinavian Cardiovascular Journal</i> , 2010, 44, 325-330.	0.4	5
370	Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. <i>European Journal of Heart Failure</i> , 2009, 11, 789-794.	2.9	37
371	Ethics in human research: when is clinical practice research?. <i>European Journal of Heart Failure</i> , 2009, 11, 531-532.	2.9	1
372	Rationale and design of the Karolinskaâ€Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2009, 11, 198-204.	2.9	47
373	Growth hormone resistance in severe heart failure resolves after cardiac transplantation. <i>European Journal of Heart Failure</i> , 2009, 11, 525-528.	2.9	20
374	What is the relationship between cardiac and peripheral ghrelin production? Reply. <i>European Journal of Heart Failure</i> , 2009, 11, 1111-1111.	2.9	1
375	Usefulness of Peak Exercise Oxygen Consumption and the Heart Failure Survival Score to Predict Survival in Patients >65 Years of Age With Heart Failure. <i>American Journal of Cardiology</i> , 2009, 103, 998-1002.	0.7	29
376	Peak VO2 in elderly patients with heart failure. <i>International Journal of Cardiology</i> , 2008, 125, 166-171.	0.8	21
377	Comparison of Peak Exercise Oxygen Consumption and the Heart Failure Survival Score for Predicting Prognosis in Women Versus Men. <i>American Journal of Cardiology</i> , 2007, 99, 399-403.	0.7	43
378	Excessive Weight Gain in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 36-41.	0.3	50

#	ARTICLE	IF	CITATIONS
379	Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. <i>American Journal of Cardiology</i> , 2005, 95, 734-741.	0.7	116
380	Heart failure in women. <i>Medical Clinics of North America</i> , 2004, 88, 1321-1345.	1.1	79
381	Primary murine cells as a model for HIV-1 infection. <i>Aids</i> , 2004, 18, 1067-1069.	1.0	2
382	Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. <i>American Journal of Cardiology</i> , 2003, 92, 1350-1354.	0.7	88
383	Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. <i>Cancer Gene Therapy</i> , 2003, 10, 365-376.	2.2	29
384	A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo. <i>Journal of General Virology</i> , 2003, 84, 603-606.	1.3	14